antyVEGF

AntyVEGF, also known as bevacizumab, is a monoclonal antibody used primarily in the treatment of cancer. It works by inhibiting the action of vascular endothelial growth factor (VEGF), a protein that plays a crucial role in the formation of new blood vessels. By blocking VEGF, antyVEGF helps to starve cancer cells of the oxygen and nutrients they need to grow and spread. This drug is commonly used in the treatment of various types of cancer, including colorectal, lung, breast, and kidney cancers, when combined with other therapies. It is typically administered through intravenous infusion. AntyVEGF was approved by the U.S. Food and Drug Administration (FDA) in 2004 and has since become a standard treatment option in many oncology settings. However, like all medications, antyVEGF can have side effects, including hypertension, proteinuria, and hemorrhage. It is important for patients to discuss these potential risks with their healthcare providers. The drug is available under the brand name Avastin.